KITE 45.99 Kite Pharma Inc. $KITE Hit a 52 week high of 48.19 Currently at 45.99 +2.35 +5.38% With a day low of 43.54 and a total volume of 1,047,600.
KITE Kite Pharma Inc. Recent Headline News
Kite Pharma to Participate in Three Upcoming Investor Conferences in November 2014
GlobeNewswire - Wed Nov 05, 7:07AM CST
Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that members of the Company's management team will participate in three upcoming conferences in November 2014:
KITE: 45.99 (+2.35)
'Mad Money' Lightning Round: Take EOG Resources Over Chesapeake Energy
at The Street - Thu Oct 23, 5:00AM CDT
Cramer prefers Celgene over Kite Pharma, General Electric over Babcock & Wilcox and sees a red flag over Ellington Financial.
SD: 3.81 (+0.27), GE: 26.41 (+0.05), ABR: 6.88 (+0.26), EMES: 83.24 (+5.42), AMGN: 160.25 (-0.10), CELG: 106.45 (-0.69), BWC: 30.29 (-0.11), KITE: 45.99 (+2.35), CHK: 23.41 (+0.65), SLW: 18.86 (+1.03), EFC: 21.84 (-0.07), EOG: 99.55 (+0.58), APA: 76.52 (+1.08)
Jim Cramer's 'Mad Money' Recap: The Machines Are Ruining the Market
at The Street - Wed Oct 22, 7:25PM CDT
The machines focus on the bad news and ignores the good, but smart investors can now move in and buy, buy, buy.
SD: 3.81 (+0.27), KO: 42.32 (+0.03), KMI: 38.75 (+0.22), MNST: 108.39 (+7.91), GE: 26.41 (+0.05), EMES: 83.24 (+5.42), ABR: 6.88 (+0.26), HON: 96.77 (+0.06), GMCR: 152.90 (-0.16), AMGN: 160.25 (-0.10), BA: 124.45 (-0.13), CELG: 106.45 (-0.69), YHOO: 48.55 (+0.62), BWC: 30.29 (-0.11), KITE: 45.99 (+2.35), CHK: 23.41 (+0.65), CMG: 649.03 (+1.91), SLW: 18.86 (+1.03), EOG: 99.55 (+0.58), EFC: 21.84 (-0.07), APA: 76.52 (+1.08), GOOGL: 551.82 (+0.13), AAPL: 109.01 (+0.31), DOW: 49.50 (-0.31), BABA: 114.56 (+2.99)
IPO Stock Watch: Biotech Forward Pharma Falls On IPO
at Investor's Business Daily - Wed Oct 15, 3:06PM CDT
Forward Pharma, the largest biotech IPO this year, tanked on its first day of trading. Denmark-based Forward Pharma (FWP) raised $221 million by pricing 10.5 million shares at 21, the midpoint of its 20-22 range. The stock was trading near 17.50,...
DM: 33.04 (+0.79), BIIB: 320.75 (-2.72), KITE: 45.99 (+2.35), FWP: 21.05 (+0.05), XENE: 13.29 (+1.32), ATRA: 28.75 (+3.95), VBAY: (), GWB: 20.04 (+0.20)
IPO Calendar: Biotech Companies Lead List Of 7 IPOs
at Investor's Business Daily - Mon Oct 13, 3:33PM CDT
In a big year for biotech IPOs, four more are scheduled to debut this week, including the year's largest -- Forward Pharma. Seven initial public offerings in total are expected this week, looking to raise a combined $1.7 billion. Forward Pharma (FWP)...
DM: 33.04 (+0.79), BIIB: 320.75 (-2.72), FWP: 21.05 (+0.05), KITE: 45.99 (+2.35), XENE: 13.29 (+1.32), MRK: 59.34 (+0.08), CFG: 23.97 (-0.33), ZAYO: 23.59 (+0.01), ATRA: 28.75 (+3.95), TEVA: 57.70 (-1.02), VBAY: (), GWB: 20.04 (+0.20)
Kite Pharma Announces Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells
GlobeNewswire - Mon Oct 13, 7:00AM CDT
Phase 1 Clinical Trial Highlights:
KITE: 45.99 (+2.35)
Kite Pharma to Participate in Gene Therapy Panel at the BIO Investor Forum
GlobeNewswire - Fri Oct 03, 5:30PM CDT
Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that David Chang, M.D., Ph.D., Kite Pharma's Executive Vice President, Research and Development, and Chief Medical Officer, will participate in the "T-Cell Therapies: Best Bets in Pushing Down the Cost Curve and Prioritizing Cancer Targets" panel at the 13th Annual BIO Investor Forum on Tuesday, October 7, 2014, at 9:00 am PDT in San Francisco, CA.
KITE: 45.99 (+2.35)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Sep 26, 7:14PM CDT
Cramer will be looking for more opportunities, especially ones made better by any additional volatility.
F: 14.17 (-0.02), MKC: 72.76 (-0.11), NKE: 93.78 (-0.82), INVN: 15.20 (-0.47), M: 59.88 (+0.84), GLUU: 3.71 (+0.10), BWLD: 157.51 (+1.43), SLB: 98.73 (+1.75), YHOO: 48.55 (+0.62), ESRT: 15.85 (-0.09), AAPL: 109.01 (+0.31), WAG: 66.92 (+0.27), ECL: 112.48 (+0.54), HCP: 43.19 (+0.07), SWKS: 59.88 (-2.26), HAL: 53.86 (+0.69), STZ: 93.56 (+0.03), MGM: 21.94 (+0.07), FINL: 26.57 (-0.48), ADS: 283.61 (-1.37), TTWO: 26.16 (+0.04), WPG: 17.78 (-0.10), WEX: 113.83 (+0.12), KITE: 45.99 (+2.35), AOL: 42.68 (+0.45), FLT: 149.18 (-1.29), AGIO: 72.06 (-11.03), MRO: 34.39 (+0.05)
Kite Pharma to Present at the 21st Annual NewsMakers in the Biotech Industry Investment Conference on Friday, September 26
GlobeNewswire - Tue Sep 16, 11:55AM CDT
Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that Arie Belldegrun, M.D., FACS, President and Chief Executive Officer, will provide an overview of the Company at the 21st Annual BioCentury NewsMakers Conference during a live presentation at 11:30am ET. Dr. Belldegrun will also be available to participate in one-on-one meetings with investors who are registered to attend the conference. The event will be held at the Millennium Broadway Hotel & Conference Center in New York. A live webcast will be accessible through Kite's website at www.kitepharma.com in the Investors section under Events & Presentations. A replay will also be available.
KITE: 45.99 (+2.35)
Upcoming Conferences, Market Activity, Drug Approval, and Earnings Release - Research Reports on Mallinckrodt, Vertex Pharmaceuticals, Kite, Bristol-Myers Squibb and Arrowhead
PR Newswire - Fri Aug 29, 7:40AM CDT
Today, Analysts Review released its research reports regarding Mallinckrodt plc (NYSE: MNK), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Kite Pharma, Inc. (NASDAQ: KITE), Bristol-Myers Squibb Company (NYSE: BMY) and Arrowhead Research Corp. (NASDAQ: ARWR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6071-100free.
MNK: 91.06 (-3.49), VRTX: 115.93 (-1.36), ARWR: 6.06 (-0.24), KITE: 45.99 (+2.35), BMY: 58.32 (-0.14), MS: 35.66 (+0.35)
The Zacks Analyst Blog Highlights: InterMune, Kite Pharma, Amicus, Celgene and Bristol-Myers Squibb
PR Newswire - Thu Aug 28, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the InterMune (Nasdaq:ITMN-Free Report), Kite Pharma (NASDAQ:KITE-Free Report), Amicus (Nasdaq:FOLD-Free Report), Celgene (Nasdaq:CELG-Free Report) and Bristol-Myers Squibb (NYSE:BMY-Free Report).
KITE: 45.99 (+2.35), CELGZ: 3.24 (-0.04)
Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 27, 9:32AM CDT
Roche's agreement to acquire InterMune has raised hopes for more such deals in the biotech sector.
KITE: 45.99 (+2.35), ACHN: 10.11 (-0.15), ITMN: 73.89 (-0.02), ALXN: 193.81 (+0.67), PBYI: 236.89 (-3.28), FOLD: 5.72 (-0.16), CELG: 106.45 (-0.69)
Kite Pharma (KITE) Shows Strength: Stock Rises 17.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 8:39AM CDT
Kite Pharma, Inc. (KITE) was a big mover last session, as its shares rose almost 18% on the day.
CBPO: 68.90 (-0.08), CBM: 22.66 (-0.82), KITE: 45.99 (+2.35), GILD: 106.45 (-0.49)
Kite Pharma Drug Fares Well in Non-Hodgkin's Lymphoma Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 5:44PM CDT
Kite Pharma, Inc. (KITE) announced the publication of positive results from an ongoing phase I-IIa study on KTE-C19 for aggressive non-Hodgkin's lymphoma.
SGEN: 36.05 (+1.20), GILD: 106.45 (-0.49), KITE: 45.99 (+2.35), AMGN: 160.25 (-0.10)
Why Kite Pharma Inc. Shares Took Off
Sean Williams, The Motley Fool - Motley Fool - Tue Aug 26, 1:24PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Kite Pharma , a clinical-stage...
KITE: 45.99 (+2.35)
Why Kite Pharma (KITE) Stock Continues to Surge Today
at The Street - Tue Aug 26, 10:21AM CDT
Kite Pharma (KITE) continued to surge Tuesday after the company published successful data from its Phase 1-2a clinical trial of patients with aggressive non-Hodgkins lymphoma.
KITE: 45.99 (+2.35)
Stock Futures Off Early Highs; July Durable Goods Orders Surge
at Investor's Business Daily - Tue Aug 26, 8:05AM CDT
Stock futures were up, although below early highs ahead of Tuesday's open despite a broad-jump surprise in July durable goods data. Dow futures were 18.1 points ahead of fair market value, down from a 27-point gain in earlier trade. Nasdaq 100...
DSW: 31.19 (-0.24), KITE: 45.99 (+2.35), BHK: 13.36 (-0.02), THI: 81.69 (+0.12)
Kite Pharma to Present at the Citi 9th Annual Biotech Conference on Wednesday, September 3
GlobeNewswire - Tue Aug 26, 6:37AM CDT
Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced its participation at Citi's 9th Annual Biotech Conference at the Mandarin Oriental in Boston on Wednesday, September 3rd, at 6:00pm ET. Arie Belldegrun, M.D., FACS, President and Chief Executive Officer, will discuss Kite's development efforts on a panel titled, "How CAR-T Cell Therapies are Shaping Oncology's Future."
KITE: 45.99 (+2.35)
KITE PHARMA
at Investor's Business Daily - Mon Aug 25, 6:00PM CDT
KITE PHARMA (KITE) reported positive results from its phase 1-2a trial for aggressive non-Hodgkin's lymphoma. Shares soared 30% to 29, near an all-time high for the June IPO .
KITE: 45.99 (+2.35)
Why Kite Pharma (KITE) Stock Is Soaring in After-Hours Trading Today
at The Street - Mon Aug 25, 4:26PM CDT
Kite Pharma (KITE) soared in after-hours trading on Monday after the company published successful data from its Phase 1-2a clinical trial of patients with aggressive non-Hodgkins lymphoma.
KITE: 45.99 (+2.35)
KITE Kite Pharma Inc. Recent Headline News
Kite Pharma to Participate in Three Upcoming Investor Conferences in November 2014
GlobeNewswire - Wed Nov 05, 7:07AM CST
Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that members of the Company's management team will participate in three upcoming conferences in November 2014:
KITE: 45.99 (+2.35)
'Mad Money' Lightning Round: Take EOG Resources Over Chesapeake Energy
at The Street - Thu Oct 23, 5:00AM CDT
Cramer prefers Celgene over Kite Pharma, General Electric over Babcock & Wilcox and sees a red flag over Ellington Financial.
SD: 3.81 (+0.27), GE: 26.41 (+0.05), ABR: 6.88 (+0.26), EMES: 83.24 (+5.42), AMGN: 160.25 (-0.10), CELG: 106.45 (-0.69), BWC: 30.29 (-0.11), KITE: 45.99 (+2.35), CHK: 23.41 (+0.65), SLW: 18.86 (+1.03), EFC: 21.84 (-0.07), EOG: 99.55 (+0.58), APA: 76.52 (+1.08)
Jim Cramer's 'Mad Money' Recap: The Machines Are Ruining the Market
at The Street - Wed Oct 22, 7:25PM CDT
The machines focus on the bad news and ignores the good, but smart investors can now move in and buy, buy, buy.
SD: 3.81 (+0.27), KO: 42.32 (+0.03), KMI: 38.75 (+0.22), MNST: 108.39 (+7.91), GE: 26.41 (+0.05), EMES: 83.24 (+5.42), ABR: 6.88 (+0.26), HON: 96.77 (+0.06), GMCR: 152.90 (-0.16), AMGN: 160.25 (-0.10), BA: 124.45 (-0.13), CELG: 106.45 (-0.69), YHOO: 48.55 (+0.62), BWC: 30.29 (-0.11), KITE: 45.99 (+2.35), CHK: 23.41 (+0.65), CMG: 649.03 (+1.91), SLW: 18.86 (+1.03), EOG: 99.55 (+0.58), EFC: 21.84 (-0.07), APA: 76.52 (+1.08), GOOGL: 551.82 (+0.13), AAPL: 109.01 (+0.31), DOW: 49.50 (-0.31), BABA: 114.56 (+2.99)
IPO Stock Watch: Biotech Forward Pharma Falls On IPO
at Investor's Business Daily - Wed Oct 15, 3:06PM CDT
Forward Pharma, the largest biotech IPO this year, tanked on its first day of trading. Denmark-based Forward Pharma (FWP) raised $221 million by pricing 10.5 million shares at 21, the midpoint of its 20-22 range. The stock was trading near 17.50,...
DM: 33.04 (+0.79), BIIB: 320.75 (-2.72), KITE: 45.99 (+2.35), FWP: 21.05 (+0.05), XENE: 13.29 (+1.32), ATRA: 28.75 (+3.95), VBAY: (), GWB: 20.04 (+0.20)
IPO Calendar: Biotech Companies Lead List Of 7 IPOs
at Investor's Business Daily - Mon Oct 13, 3:33PM CDT
In a big year for biotech IPOs, four more are scheduled to debut this week, including the year's largest -- Forward Pharma. Seven initial public offerings in total are expected this week, looking to raise a combined $1.7 billion. Forward Pharma (FWP)...
DM: 33.04 (+0.79), BIIB: 320.75 (-2.72), FWP: 21.05 (+0.05), KITE: 45.99 (+2.35), XENE: 13.29 (+1.32), MRK: 59.34 (+0.08), CFG: 23.97 (-0.33), ZAYO: 23.59 (+0.01), ATRA: 28.75 (+3.95), TEVA: 57.70 (-1.02), VBAY: (), GWB: 20.04 (+0.20)
Kite Pharma Announces Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells
GlobeNewswire - Mon Oct 13, 7:00AM CDT
Phase 1 Clinical Trial Highlights:
KITE: 45.99 (+2.35)
Kite Pharma to Participate in Gene Therapy Panel at the BIO Investor Forum
GlobeNewswire - Fri Oct 03, 5:30PM CDT
Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that David Chang, M.D., Ph.D., Kite Pharma's Executive Vice President, Research and Development, and Chief Medical Officer, will participate in the "T-Cell Therapies: Best Bets in Pushing Down the Cost Curve and Prioritizing Cancer Targets" panel at the 13th Annual BIO Investor Forum on Tuesday, October 7, 2014, at 9:00 am PDT in San Francisco, CA.
KITE: 45.99 (+2.35)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Sep 26, 7:14PM CDT
Cramer will be looking for more opportunities, especially ones made better by any additional volatility.
F: 14.17 (-0.02), MKC: 72.76 (-0.11), NKE: 93.78 (-0.82), INVN: 15.20 (-0.47), M: 59.88 (+0.84), GLUU: 3.71 (+0.10), BWLD: 157.51 (+1.43), SLB: 98.73 (+1.75), YHOO: 48.55 (+0.62), ESRT: 15.85 (-0.09), AAPL: 109.01 (+0.31), WAG: 66.92 (+0.27), ECL: 112.48 (+0.54), HCP: 43.19 (+0.07), SWKS: 59.88 (-2.26), HAL: 53.86 (+0.69), STZ: 93.56 (+0.03), MGM: 21.94 (+0.07), FINL: 26.57 (-0.48), ADS: 283.61 (-1.37), TTWO: 26.16 (+0.04), WPG: 17.78 (-0.10), WEX: 113.83 (+0.12), KITE: 45.99 (+2.35), AOL: 42.68 (+0.45), FLT: 149.18 (-1.29), AGIO: 72.06 (-11.03), MRO: 34.39 (+0.05)
Kite Pharma to Present at the 21st Annual NewsMakers in the Biotech Industry Investment Conference on Friday, September 26
GlobeNewswire - Tue Sep 16, 11:55AM CDT
Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that Arie Belldegrun, M.D., FACS, President and Chief Executive Officer, will provide an overview of the Company at the 21st Annual BioCentury NewsMakers Conference during a live presentation at 11:30am ET. Dr. Belldegrun will also be available to participate in one-on-one meetings with investors who are registered to attend the conference. The event will be held at the Millennium Broadway Hotel & Conference Center in New York. A live webcast will be accessible through Kite's website at www.kitepharma.com in the Investors section under Events & Presentations. A replay will also be available.
KITE: 45.99 (+2.35)
Upcoming Conferences, Market Activity, Drug Approval, and Earnings Release - Research Reports on Mallinckrodt, Vertex Pharmaceuticals, Kite, Bristol-Myers Squibb and Arrowhead
PR Newswire - Fri Aug 29, 7:40AM CDT
Today, Analysts Review released its research reports regarding Mallinckrodt plc (NYSE: MNK), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Kite Pharma, Inc. (NASDAQ: KITE), Bristol-Myers Squibb Company (NYSE: BMY) and Arrowhead Research Corp. (NASDAQ: ARWR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6071-100free.
MNK: 91.06 (-3.49), VRTX: 115.93 (-1.36), ARWR: 6.06 (-0.24), KITE: 45.99 (+2.35), BMY: 58.32 (-0.14), MS: 35.66 (+0.35)
The Zacks Analyst Blog Highlights: InterMune, Kite Pharma, Amicus, Celgene and Bristol-Myers Squibb
PR Newswire - Thu Aug 28, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the InterMune (Nasdaq:ITMN-Free Report), Kite Pharma (NASDAQ:KITE-Free Report), Amicus (Nasdaq:FOLD-Free Report), Celgene (Nasdaq:CELG-Free Report) and Bristol-Myers Squibb (NYSE:BMY-Free Report).
KITE: 45.99 (+2.35), CELGZ: 3.24 (-0.04)
Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 27, 9:32AM CDT
Roche's agreement to acquire InterMune has raised hopes for more such deals in the biotech sector.
KITE: 45.99 (+2.35), ACHN: 10.11 (-0.15), ITMN: 73.89 (-0.02), ALXN: 193.81 (+0.67), PBYI: 236.89 (-3.28), FOLD: 5.72 (-0.16), CELG: 106.45 (-0.69)
Kite Pharma (KITE) Shows Strength: Stock Rises 17.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 8:39AM CDT
Kite Pharma, Inc. (KITE) was a big mover last session, as its shares rose almost 18% on the day.
CBPO: 68.90 (-0.08), CBM: 22.66 (-0.82), KITE: 45.99 (+2.35), GILD: 106.45 (-0.49)
Kite Pharma Drug Fares Well in Non-Hodgkin's Lymphoma Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 5:44PM CDT
Kite Pharma, Inc. (KITE) announced the publication of positive results from an ongoing phase I-IIa study on KTE-C19 for aggressive non-Hodgkin's lymphoma.
SGEN: 36.05 (+1.20), GILD: 106.45 (-0.49), KITE: 45.99 (+2.35), AMGN: 160.25 (-0.10)
Why Kite Pharma Inc. Shares Took Off
Sean Williams, The Motley Fool - Motley Fool - Tue Aug 26, 1:24PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Kite Pharma , a clinical-stage...
KITE: 45.99 (+2.35)
Why Kite Pharma (KITE) Stock Continues to Surge Today
at The Street - Tue Aug 26, 10:21AM CDT
Kite Pharma (KITE) continued to surge Tuesday after the company published successful data from its Phase 1-2a clinical trial of patients with aggressive non-Hodgkins lymphoma.
KITE: 45.99 (+2.35)
Stock Futures Off Early Highs; July Durable Goods Orders Surge
at Investor's Business Daily - Tue Aug 26, 8:05AM CDT
Stock futures were up, although below early highs ahead of Tuesday's open despite a broad-jump surprise in July durable goods data. Dow futures were 18.1 points ahead of fair market value, down from a 27-point gain in earlier trade. Nasdaq 100...
DSW: 31.19 (-0.24), KITE: 45.99 (+2.35), BHK: 13.36 (-0.02), THI: 81.69 (+0.12)
Kite Pharma to Present at the Citi 9th Annual Biotech Conference on Wednesday, September 3
GlobeNewswire - Tue Aug 26, 6:37AM CDT
Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced its participation at Citi's 9th Annual Biotech Conference at the Mandarin Oriental in Boston on Wednesday, September 3rd, at 6:00pm ET. Arie Belldegrun, M.D., FACS, President and Chief Executive Officer, will discuss Kite's development efforts on a panel titled, "How CAR-T Cell Therapies are Shaping Oncology's Future."
KITE: 45.99 (+2.35)
KITE PHARMA
at Investor's Business Daily - Mon Aug 25, 6:00PM CDT
KITE PHARMA (KITE) reported positive results from its phase 1-2a trial for aggressive non-Hodgkin's lymphoma. Shares soared 30% to 29, near an all-time high for the June IPO .
KITE: 45.99 (+2.35)
Why Kite Pharma (KITE) Stock Is Soaring in After-Hours Trading Today
at The Street - Mon Aug 25, 4:26PM CDT
Kite Pharma (KITE) soared in after-hours trading on Monday after the company published successful data from its Phase 1-2a clinical trial of patients with aggressive non-Hodgkins lymphoma.
KITE: 45.99 (+2.35)
